Hepatocellular Carcinoma

Trientine Dismantles Growth, Cuts Off Tumor Nourishment In Liver Cancer

Published in Hepatitis Weekly, December 17th, 2001

by Sonia Nichols, senior medical writer - A therapeutic alternative for Wilson disease could also benefit patients with hepatocellular carcinoma, a form of primary liver cancer.

Doctors in Japan say that based on murine models, the copper chelating agent trientine dihydrochloride could be used for reducing angiogenesis in hepatocellular carcinoma (HCC), one of the most common forms of cancer in the world. If so, the thousands of patients who develop HCC each year, whether due to liver cirrhosis, viral hepatitis, alcohol use, or liver toxins, would profit from the new treatment strategy.

"Since HCC is known as a hypervascular tumor, antiangiogenesis...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry